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Abstract
Purpose. Although pre-operative chemotherapy has improved the prognosis for individuals with osteosarcoma,approximately
40% of patients will die of their disease.The aim of this study was to quantitate proliferative activity in high grade osteosar-
comas and to determine whether proliferation is a prognostic factor.
Patients. The study consisted of 27 patients with high grade non-metastatic osteosarcoma at various sites for whom
pre-operative biopsies and resection specimens were available for review. All patients were treated similarly and had at least
24 months’ follow-up from the date of diagnosis.
Methods. Proliferative activity (Ki-67 expression) was examined in the diagnostic biopsies immunohistochemically using
the MIB-1 antibody. Proliferation was quantitated in two ways; (1) the number of immunopositive cells was counted manu-
ally using an ocular grid; or (2) the percentage of immunopositive nuclear area was assessed using morphometric image
analysis. Proliferative index was evaluated in relation to patient outcome.
Results. Proliferative activity was seen in all biopsies.The median proliferative index as determined by counting cells was
24% (mean of 27%, range of 7± 61%) and by image analysis was 2% (mean 3%, range 0.32± 8.4).The correlation between
MIB-1 proliferation indicesdeterminedeitherby image analysis methodology or manual cellcountingwas high (Spearman’s
rho=0.79). Proliferative index did not appear to predict either disease-free or overall survival.
Discussion. Tumor proliferation does not appear to be prognostic for high grade osteosarcomas.Whether assessment of this
feature in conjunction with other tumor characteristics might be prognostic requires further study.
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With the addition of pre-operative chemotherapy to
the treatment regimen for osteosarcoma the 5 year
survival rates have increased,although approximately
30± 40% of patients still succumb to the disease.
1,2
The current challenge is to delineate those patients
who have a worse prognosis. It is well accepted that
tumor grade in¯ uences prognosis as low grade oste-
osarcomas have little metastatic potential;
3 however,
the identi® cation of signi® cant prognostic indicators
for high grade osteosarcoma has been elusive.
Although several studies have suggested that a variety
of factors such as age, sex, tumor size and site at the
time of presentation
2,4 may be of prognostic value, a
critical analysis of the literature demonstrated that
only tumor necrosis after chemotherapy has predic-
tive value.
5Patients whose tumorsafter chemotherapy
show greater than 90% tumornecrosisin the resected
specimen histologically had a continuous disease-
free survival of 91%, as compared to 14% for those
with tumoral necrosis of less than 90%.
6 However,
this parameter cannot be used to predict those who
will respond to chemotherapy as necrosis is only
determined after chemotherapy has been given.
There is an increasing body of literature
demonstrating that certain chemotherapeutic agents,
such as cis-platin which is used in the treatment of
osteosarcoma,act by inducingcellularapoptosis rather
than having a direct toxic action on the cells.
7± 13
Apoptosis follows a regulated pathway and allows for
the elimination of abnormal or genetically damaged
cells.
14,15 As programmed cell death occurs
predominately in proliferating cells, we postulated
that osteosarcomaswith a high proliferative rate would
be more sensitive to chemotherapy and that assessing
proliferation in the tumor pre-operatively might be a
way to predict prognosis. In keeping with this
hypothesis it has been shown that an increased
proliferative index is prognostic for a wide variety of
tumors.
16± 20
In this retrospective study, proliferation was
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of osteosarcomas by immunostaining for Ki-67
expression using the MIB-1 antibody.The prolifera-
tion index was quantitated in two ways: (1) manual
cell counting using an ocular grid; or (2) by
determining the percentage of immunopositive
nuclear area using morphometric image analysis.
Proliferative activity was then evaluated in relation to
the clinical outcome.
Materials and methods
Clinical and tissue information
Between 1989 and 1996, 27 patients with nonmeta-
static osteosarcoma,for whom both biopsy and tumor
resection specimensand clinicalfollow-up were avail-
able, were retrieved from the ® les of Mount Sinai
Hospital. Low grade or surface osteosarcomas, oste-
osarcomas of the jaw or soft tissue, and osteosar-
comas arising in pre-existing bone disease such as
Paget’s disease were excluded.As well patients whose
biopsies had been decalci® ed prior to paraffin-
embedding were excluded from the study as this can
affect immunoreactivity.
21All patients received three
courses of chemotherapy which included adriamycin
(75 mg/m
2) for 3 days and cis-platin (100 mg/m
2)
prior to resection of the tumor and three courses of
chemotherapy post-operatively.The minimumlength
of follow-up was 2 years from diagnosis.
The biopsies were ® xed in 10% buffered formalin,
and paraffin-embedded. Histological sections were
stained with hematoxylin and eosin and examined
microscopically.The tumor resection specimenswere
serially cut using a band saw, and X-rayed.
Representative tumor sections, selected after review
of the specimen X-ray and the gross appearance and
representing approximately 30± 50% of the tumor,
were submitted for histological examination. The
tissue was ® xed in formalin for at least 24 hours,
decalci® ed in 10% formic acid, and then paraffin-
embedded.Five micronsections were cut and stained
with hematoxylin and eosin. The percent of tumor
which had undergone necrosis was estimated histo-
logically in each slide which contained tumor.
Immunohistochemistry
A representative section from each biopsy was
dewaxed, microwave pretreated (23 5 min in antigen
retrieval solution; Vector, Burlingame, CA), and
blocked with a universal blocking agent (Signet
Laboratories, Inc., Dedham, MA).The sections were
incubated with antibody reactive with Ki-67 (MIB-1
at 1:50 dilution; AMAC Inc., Westbrook, ME)
overnight.The negative control included leaving out
the primary antibody.Immunoreactivitywas detected
using a biotinylated secondary antibody and an
avidin± biotin peroxidase complex detection system
(Vectastain, Vector, Burlingame,CA) using the chro-
magen 3-3© -diaminobenzidine tetrahydrochloride
(Sigma Chemical Co., St. Louis, MI). The sections
were counterstained with hematoxylin. In order to
diminish the subjectivity of scoring,a brown nuclear
reaction product of any intensity was considered a
positive reaction.
Assessment of proliferative index
Cell counts. The sections were scannedat low power,
the areas in the tumor with the highest proliferative
activity were selected and the MIB-1 labeled cells
were counted usingan oculargrid at 2503 magni® ca-
tion.Three hundred tumor cells were counted,and if
there were not 300 cells then all the tumor cells in the
section were counted. All sections were counted at
least twice by two observers who had no knowledge
of the clinical outcome.Whenthere was a discrepancy
(>5% difference) between the counts, the two
observers examined the slide under a multi-headed
microscopeand recountedthe slide.The proliferative
index was calculated as percentof the positive MIB-1
stained nuclei over the total number of tumor cell
nuclei counted and the ® nal value was the mean of
the two readings.
Image analysis. The immunostained tissue sections
were analyzed by light microscopy,with a 403 objec-
tive (4003 magni® cation), and the Quantimet 500
MC image analysis system equipped with a color
camera (Leica, Canada) by one observer (R.J.) who
had no knowledge of the clinical outcome. Areas
composedpredominantlyof tumor were selected and
areas of reactive bone and ® brosis, hemorrhage and
in¯ ammation were preferentially excluded. Thirty
consecutive ® elds (0.026 mm
2/® eld) were analyzed,
starting from the lower left hand corner of each slide.
The total positive stained area for each ® eld was
thresholded and a series of segmentation and ® ll
commands were made manually using the edit
command.The total positive area was related to the
total ® eld area measured. The percentage positive
nuclear staining for each ® eld was calculated by the
Quantimet 500 MC system as the percentage of
immunopositive nuclear area over the total ® eld area.
The intraobserver variability was on average 12%
(data not shown).
Statistical analysis. Descriptive statistics including
means, standard deviations and frequencies were
calculated for sample descriptors and proliferation as
appropriate.As proliferationwas calculated usingtwo
methods, Spearman’s rho was calculated to evaluate
the relationship between the results. Similarly, the
correlation of proliferation to tumor necrosis after
pre-operative chemotherapy was evaluated.Prolifera-
tion was then dichotomizedat the median value (24%)
and compared to tumor necrosis dichotomized at
90% and then 95%. Proliferation as a predictor of
48 R.Jong et al.disease-free survival and overall survival was evalu-
ated using the method of Kaplan and Meier
22 with
the date of diagnosis as time zero.
Results
Patient characteristics
As shown in Table 1, the patients consisted of 17
males and 10 females with a median age of 20 years
(range14± 64 years).The sites of involementincluded
femur (n=12), tibia (n=3), humerus (n=1), radius
(n=2), ® bula (n=5), and pelvis (n=4). The mean
maximal diameter of the tumor was 9.6 cm (range
4± 17 cm).There were 4 stage IIA, and 23 stage IIB
tumors.There were no obvious differences between
stage IIA or IIB tumors in terms of tumor size or
clinical course suggesting they could be analyzed
togetheras onegroup.Eleven of the 27 patients (41%)
relapsedsystemically.The median disease-freesurvival
for the entire group from the time of biopsy was 34
months (range from 4± 93 months) (Table 2). The
median overall survival was 39 months (range from
6± 93 months) (Table 2).
Pathology
Review of the biopsies demonstrated the presence of
osteosarcoma as characterized by the presence of
malignant cells producing osteoid.
3The subtypes of
osteosarcoma included osteoblastic, chondroblastic,
® broblastic, giant cell rich and small cell subtypes.
The biopsies showed variable amounts of necrosis.
Residual osteosarcoma was seen in all but three of
the resected tumors.When single cells with enlarged
hyperchromatic smudgednucleiwere seen these were
interpreted as residual tumor cells. The tumors
showed a variety of changes including overt necrosis,
or tumor cell drop out with the pre-existing matrix
remaining. In areas, the tumor had been replaced
with ® brovascular tissue with or without ossi® cation
and these were considered reparative changes indica-
tive of remote tumor necrosis and were included in
the determination of tumor necrosis.The estimated
amount of necrosis in the resected specimens varied
between 5 and 100% (Table 2). Twelve of the 27
patients had greater than 90% tumor necrosis with 4
patients having greater than 95% tumor necrosis.
Ki-67 labeling index
Proliferative activity, as indicated by Ki-67 (MIB-1)
expression detected by immunohistochemical
staining,was seenin all biopsies.Themedianprolifera-
tive index, as determined by manual counting was
24% (mean of 27%, range of 7± 61%) and by image
analysis was 2% (mean 3%, range 0.32± 8.4). The
proliferative index as determined by manual counts
Figure 1. Photomicrograph of osteosarcoma showing Ki-67 immunoreactivity as indicated by dark nuclear staining (immunoperoxi-
dase,hematoxylin counterstain, magni® cation 3 400).
Proliferative activity in osteosarcoma 49showed a signi® cant correlation with the proliferative
index as determined by morphometricquantification
of the percentage of Ki-67 positive nuclear area
(Spearman’s rho=0.79, p<0.001).
Correlation of Ki-67 labeling index with tumor necrosis
The correlation of proliferation, whether by manual
countingor morphometricquanti® cation,with tumor
necrosis was not signi® cantly different than 0
(rho=0.25, p=0.21 and rho=0.23, p=0.25,
respectively).
Ki-67 labeling index as a predictor of disease outcome
As the two methods of quantifying proliferation were
highly correlated, manual counting was arbitrarily
chosen to evaluate the relationship of proliferation to
disease-free and overall survival. Figure 2 shows that
there was overlap in the proliferation values based on
whether the patient developed systemic disease or
not. Similarly, the time to systemic relapse (p=0.90)
and overall survival (p=0.54) were not signi® cantly
different when proliferation was dichotomized at the
median of the manual count, that is <24% or ‡ 24%
(Fig. 3). Five of 13 patients with tumors showing
<24% proliferation relapsed as compared to 6 of 14
patients with tumors showing ‡ 24% proliferation.As
of last follow-up 5 patients had died of their disease
(3 of 13 with proliferation <24% and 2 of 14 with
proliferation ‡ 24%).
Discussion
This study demonstrated that either manual cell
counting or image morphometry can be used to
determineproliferative index.However,the prolifera-
tion index,quanti® ed in pretreatmentbiopsies of high
grade osteosarcoma following immunohistochemical
staining with the MIB-1 antibody, was not a
prognosticindicator for either disease-free survival or
overall survival.The follow-up time of 2 years which
was used in this study is adequate to assess disease-
free and overall survival as systemic metastases will
develop in up to 94% of patients within 18 months of
surgery.
6
Two different methods were used to determine
tumor proliferation; one was the standard method of
counting cells using an ocular grid and the other
utilized image analysis to quantify immunoreactivity
by measuring the percent of immunopositive nuclear
area.This latter approach has been utilized to predict
prognosisin other tumor types.
19,23± 25Both methods
of quanti® cation were done to ensure that the way of
determiningcell proliferation was not in¯ uencing the
results. There was a high correlation (rho=0.79)
between the manualcountingof thefraction of MIB-1
positive cells and the percentage area of MIB-1
nuclear positivity as measuredby image analysis.This
is in keeping with the report by Caulet et al.
26 who
demonstrated in non-Hodgkin’s lymphoma a similar
correlation between proliferative indices determined
by cell counting and by image analysis. It is unlikely
Table 1. Clinical features
Case Age (yrs) Gender Site Tumor size (cm)* Stage²
1 32 male femur 4.9 IIA
2 23 male tibia 6.8 IIB
3 20 female pelvis 14 IIB
4 14 female radius 7.5 IIB
5 29 female tibia 9 IIB
6 21 male radius 8.5 IIB
7 16 male humerus 8 IIB
8 18 female ® bula 6.5 IIB
9 31 male femur 6.5 IIA
10 15 female femur 4.7 IIB
11 47 male femur 7.5 IIA
12 20 female ® bula 4 IIB
13 31 female femur 10.2 IIB
14 21 male femur 15 IIA
15 49 male pelvis 9 IIB
16 22 male tibia 6 IIB
17 18 male femur 10 IIB
18 20 male femur 10.5 IIB
19 26 female pelvis 16 IIB
20 17 male femur 7 IIB
21 19 male ® bula 9.5 IIB
22 15 female ® bula 14.7 IIB
23 19 male femur 17 IIB
24 20 female ® bula 4 IIB
25 64 male femur 8 IIB
26 46 male pelvis 17 IIB
27 17 male femur 17 IIB
*Tumor size based on maximum diameter.
² Stage is determined according to AJCC criteria.
57
50 R.Jong et al.that the number of ® elds assessed by image analysis
in the quanti® cation of the proliferating index was a
confoundingfactor.In a pilot study,we observed that
when up to 50 ® elds were assessed, the percent posi-
tive nuclear area and the cell counts both leveled off
between 25 to 30 ® elds (data not shown).Therefore,
30 ® elds were used for quanti® cation using image
analysis.
In keeping with lack of relationship between
proliferativeindexand outcome,therewas no relation-
ship between proliferation index and tumor necrosis
of greater than 90%.This is expected as this extent of
necrosishas beenshown to be predictive of outcome.
6
Proliferative index was determined using MIB-1
27
and immunohistochemistry because the antibody
(MIB-1) can be used on paraffin-embedded tissue
and its reactivity is not affected if there is a delay in
® xation.
28± 30The useof immunohistochemistryallows
visualization of the immunoreactivity and con® rms
that it is located in tumorcells.Furthermore,prolifera-
tive indexes, determined using this approach, have
been found to be prognostic in many different tumor
types such as carcinoma,
20,31,32 lymphoma,
33
sarcoma
16± 18,34and brain tumors.
35Proliferating cell
nuclear antigen (PCNA) expression, a different
proliferation associated protein, has been used by
others to quantify proliferation.However,PCNA can
still be detected 48 hours after entry into G0 of the
cell cycle
28 and PCNA is involved in DNA repair so
the antibody can label nonproliferatingcells,
28,36both
features limit its usefulness as a proliferation marker.
There are at least four other methods to identify
proliferating cells, counting mitoses, ¯ ow cytometry,
nuclear organizer region (NOR) counts and DNA
labeling,but they also have drawbacks. Mitotic count
has been used but may underestimate the number of
proliferatingcells.
37± 39Flowcytometrydoesnotdetect
cells in G1,
38,40DNA distributions can be difficult to
interpret in aneuploid tumors,
30 and cellular debris
and nontumorcellscan beconfoundingfactors.
29,30,41
Ag NORs (silver stained NOR) counts are another
method to identify proliferating cells but they also
appear in nonproliferating cells.
42 Ag NORs counts
do not appear to estimate cell proliferation as well as
Ki-67 immunostaining
43and have been shown not to
be prognostic in osteosarcoma.
44 DNA labeling by
3H-thymidine or BrDU labeling cannot be used in
retrospective studies as the tissue has been formalin
® xed.
28
There have been four other studies
45± 48 examining
the relationshipbetween proliferation index and oste-
osarcomas,and two of these showed results similar to
the current investigation. None of these studies used
image analysis for quanti® cation. Park et al.
45 used
Table 2. Proliferative indices and clinical outcome
Case % area
% immunopositive
cells
Tumor necrosis
(%)
Systemic relapse
(mos)*
Overall survival
(mos)²
1 0.32 17 50 no ANED (83)
2 0.5 19 50 no ANED (41)
3 0.58 12 75 no ANED (87)
4 0.82 11 100 no ANED (37)
5 0.97 15 70 yes (4) DOD (16)
6 0.97 20 80 yes (20) ANED (30)
7 1.04 11 30 yes (10) ANED (82)
8 1.23 31 90 no ANED (27)
9 1.25 7 40 yes (6) DOD (23)
10 1.28 13 5 no ANED (56)
11 1.66 34 90 no ANED (86)
12 1.87 15 100 no ANED (34)
13 1.95 20 65 yes (8) DOD (17)
14 2.04 23 90 no ANED (41)
15 2.49 13 90 no ANED (26)
16 2.67 39 90 yes (24) DOD (42)
17 3.07 27 95 no ANED (35)
18 3.53 24 80 yes (17) AWED (38)
19 3.82 28 75 no ANED (37)
20 4.33 38 90 no ANED (44)
21 4.44 41 50 yes (25) AWED (39)
22 5.04 32 60 yes (32) AWED (40)
23 6.24 30 90 yes (4) DOD (6)
24 6.37 61 80 no ANED (69)
25 7.24 47 40 no ANED (93)
26 7.25 52 100 yes (10) AWED (25)
27 8.4 60 90 no ANED (88)
ANED = alive no evidence of disease;AWED = alive with disease; DOD = deceased due to disease.
* Months to relapse.
² Months of follow-up.
The proliferative indices in the biopsies of osteosarcoma, as determined by manual cell counts (% immunopositive cells) or
image analysis (% area) were related to the amount of necrosis in the resected specimen and clinical outcome.
Proliferative activity in osteosarcoma 51PCNA and MIB-1 antibodies to assess proliferation
in 34 cases of osteosarcomaand showed that prolifera-
tion was not predictive of disease-free survival.
However, in that paper, it does not state whether the
patients were all treated similarly. In the study by
Scotlandi et al.,
46 the proliferative index was
determined by measuring Ki-67 immuno¯ uores-
cence in cytospins of 30 cases of high gradenonmeta-
static osteosarcoma,which is a different method than
that used in the current study. Although patients
whose tumors had an elevated Ki-67 labeling index
showed a trend (p=0.15) towards shorter disease-free
survival at 24 months follow-up, it was not statisti-
cally signi® cant, similar to our study. In contrast, the
report by Molendini et al.
47 showed that patients
with high grade osteosarcoma and a Ki-67 labeling
index of ‡ 25%, which was the median value in that
study, was prognostic as these patients had a statisti-
cally signi® cantshorterdisease-freesurvivalthan those
with a value of less than 25%. However, this
signi® cance was lost in multivariate analysis. In that
study the labeling indexwas determinedby estimating
the percentage of positive cells which only provides
an approximate value. Furthermore,it was not stated
whether these patients were treated in a uniform way
suggesting that the study is not directly comparable
to ours. In the fourth study,
48 although signi® cantly
longer survival was observed in osteosarcomas with a
proliferative index less than 24%, the cases examined
were extraskeletal osteosarcomasand they may behave
differently than osteosarcomas of bone.
There are several possible explanations as to why
proliferative index is not prognostic for osteosar-
coma. First, the biopsy is only a small sample of the
entiretumorand the proliferative fraction in the tissue
obtained for biopsy may not be representative of the
entire tumor. This is a less likely explanation as
proliferative indices quanti® ed in biopsies have been
shown to be predictive of disease-free survival
49 or
overall survival
50 in other tumor types. Second,
although Ki-67 has been used extensively to assess
proliferation in many tumor types, a recent study has
shown that Ki-67 may not be a reliable marker of
actively proliferating cells in osteosarcomas that are
expressing p53 or the cell cycle protein p21.
51Third,
Ki-67 representsonly one componentof the cell cycle
and it is possible that changes in other cell cycle
proteins may also have to be considered as G1 phase
can be dysregulated in osteosarcoma.
52 For example,
it has been shown that loss of cyclin D1 expressionin
osteosarcoma correlates strongly with metastatic
progression and disease-free survival.
47 Fourth, the
mechanisms regulating apoptosis may contribute to
outcome.
13Wild type p53, which regulates progres-
sion to apoptosis, when mutated can resultin cellular
resistance to chemotherapy.
12Lastly,the mechanisms
causing tumor resistance to chemotherapy are
complex, and likely involve processes in addition to
cell proliferation. Expression of multi-drug resist-
ance proteins, such as mdr-1 or mrp, which limit
intracellular accumulation of various chemothera-
peutic agents are present in osteosarcoma cells
53± 56
Figure 2. Distribution of proliferative indices, as determined by manual cell counting, according to patients with no systemic relapse
and those who had systemic relapse.
52 R.Jong et al.and could contribute to drugresistance.Three studies
have shown that elevated levels of mdr-1 are associ-
ated with an adverse outcome in osteosarcoma.
54± 56
In summary, this study suggests that cell prolifera-
tion, as indicated by Ki-67 expression detected by
immunohistochemicalstaining with MIB-1 antibody
in formalin ® xed paraffin-embedded sections, can be
quanti® ed either by manualcell countsusingan ocular
grid or by determining the percent immunopositive
nuclear area by image morphometry. An increased
proliferative index, as determined in biopsies of high
grade osteosarcoma by either quanti® cation method,
does not appear to be prognostic for outcome in this
retrospective study.Assessmentof tumor cells for the
presence of changes in tumor suppressor genes or
cell cycle regulators may further enhance our ability
to predict prognosis, but this requires further
investigation.
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